(BUSINESS WIRE)--Acorda Therapeutics, Inc. today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg gross sales in the fourth quarter of 2010 were $55.7 million, and $141.4 million for the full year 2010. In addition, fourth quarter shipments of Zanaflex Capsules® (tizanidine hydrochloride) and tablets were $15.8 million in the fourth quarter of 2010 and full year shipments were $57.3 million. Zanaflex gross sales are recognized using a deferred revenue recognition model, and are not yet final. As of December 31, 2010, Acorda expects that cash, cash equivalents and short-term investments will be in excess of $235 million. The final year-end balance will be available in the company’s fourth quarter earnings report.
